Evobright

Evobright aims to discover and develop innovative cancer drugs that enable the patient's immune system to recognize and destroy cancer cells in solid tumors, thereby prolonging and improving the lives of cancer patients. Our therapeutic concept is based on mimicking bacterial infection in tumor cells, which recruits a subpopulation of human immune cells called gamma delta (γδ) T cells to destroy the labeled cells even in immunosuppressed environments. Evobright's unique technology platform with its modular antibody design provides the basis for a portfolio of cancer drugs perfectly suited for the treatment of various solid cancers.